Professor Jun Shirakawa MD PhD at Laboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, has elucidated the protective effects of the early combination therapy on β-cells under type 2 diabetes.
Imeglimin and metformin act in metabolic organs, including β-cells, via different mechanisms. In the present study, Prof Shirakawa and colleagues investigated the impacts of imeglimin, metformin, or their combination on β-cells, the liver, and adipose tissues in obese siabetic db/db mice. The combination of imeglimin and metformin was beneficial for the maintenance of β-cell mass in db/db mice, probably through direct action on β-cells, suggesting a potential strategy for protecting β-cells in the treatment of type 2 diabetes.

Check here